Predicting Readmissions Using Omics, Biostatistical Evaluate and Artificial Intelligence
Recruiting now NCT05028686
Run by Institute for Clinical Evaluative Sciences · for 18 to 105 · All sexes
What this study is about
This study is a prospective registry that aims to predict readmissions in patients with heart failure, using -omics, machine learning, patient reported outcomes, clinical data and other high-dimensional data sources.
Who can join (things the study team will check)
✅ You may be able to join if…
- Any patient aged 18 years or older admitted to hospital or seen in the emergency department with heart failure defined clinically
- The diagnosis will be guided by the Framingham criteria for HF and/or BNP. A BNP >400 will be defined as definite heart failure and BNP 100-400 classified as possible heart failure.
- Provides informed consent
🚫 You may not be able to join if…
- Patients who cannot communicate due to dementia or severe cognitive deficits
- non-Ontario residents
- nursing home residents
- those who are not discharged home but are discharged to a skilled nursing facility (long-term care or chronic institution)
- those who are unable to communicate who do not have a proxy (e.g. spouse or close family member) to facilitate communication with the patient.
Where this trial is running
- University Health Network, Toronto, Ontario, Canada
Who to contact
Douglas S Lee, MD, PhD · 4163403861 · dlee@ices.on.ca
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT05028686.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.
Beacon is an information tool, not medical advice. Whether a trial is right for you is a decision for you, your doctor, and the study team. Trial details come from the official registry, ClinicalTrials.gov, and may change — always confirm with the study team. Beacon collects no data about you: this page has no cookies, no accounts, and no tracking.